Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation

Diagnostics

Volumn 3, Issue 4, 2013, Pages 372-384

  Binderup, Tina ^a   Knigge, Ulrich Peter ^a   Federspiel, Birgitte ^a   Sommer, Peter ^a   Hasselby, Jane Preuss ^a   Loft, Annika ^a   Kjaer, Andreas ^a  

^a University of Copenhagen   (Denmark)

Author keywords

FDG PET; Gene expression; Glucose; Imaging; Neuroendocrine tumors; Proliferation index

Indexed keywords

EID: 84892962904     PISSN: None     EISSN: 20754418     Source Type: Journal    
DOI: 10.3390/diagnostics3040372     Document Type: Article

References (33)

1. Brown, R.S.; Leung, J.Y.; Kison, P.V.; Zasadny, K.R.; Flint, A.; Wahl, R.L. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J. Nucl. Med. 1999, 40, 556–565.
2. Kloppel, G.; Couvelard, A.; Perren, A.; Komminoth, P.; McNicol, A.M.; Nilsson, O.; Scarpa, A.; Scoazec, J.Y.; Wiedenmann, B.; Papotti, M.; Rindi, G.; Plockinger U.; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Guidelines for the Standards of Care in Patients with Neuroendocrine Tumors: Towards a Standardized Approach to the Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors and Their Prognostic Stratification. Neuroendocrinology 2008, 90, 162–166.
3. Rindi, G.; Arnold, R.; Bosman, F.T.; Capella, C.; Klimstra, D.S.; Kloppel, G.; Komminoth, P.; Solcia, E. Nomenclature and Classification of Neuroendocrine Neoplasms of the Digestive System. In WHO Classification of Tumours of the Digestive System; IARC Press: Lyon, France, 2010.
4. 18 F-FDG PET. J. Nucl. Med. 2010, 51, 704–712.
5. 18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT1 and hexokinase II. Acta Radiol. 2008, 49, 1145–1153.
6. Aloj, L.; Caracó, C.; Jagoda, E.; Eckelman, W.C.; Neumann, R.D. GLUT1 and hexokinase expression: Relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res. 1999, 59, 4709–4714.
7. 18 F]FDG uptake in non-small cell lung cancer. Eur. J. Nucl. Med. 2000, 27, 1778–1785.
8. Mathupala, S.P.; Ko, Y.H.; Pedersen, P.L. Hexokinase II: Cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006, 25, 4777–4786.
9. Watson, A.J.; Lolohea, S.; Robertson, G.M.; Frizelle, F.A. The role of positron emission tomography in the management of recurrent colorectal cancer: A review. Dis. Colon Rectum 2007, 50, 102–114.
10. de Geus-Oei, L.F.; Ruers, T.J.M.; Punt, C.J.A.; Leer, J.W.; Corstens, F.H.M.; Oyen, W.J.G. FDG-PET in colorectal cancer. Cancer Imaging 2006, 6, S71–S81.
11. 18F-2-fluoro-2-deoxy-D: Glucose uptake by positron emission tomography in colorectal cancer. Digest Dis. Sci. 2006, 51, 2198–2205.
12. Song, Y.S.; Lee, W.W.; Chung, J.H.; Park, S.Y.; Kim, Y.K.; Kim, S.E. Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer 2008, 61, 54–60.
13. Hutchings, M.; Loft, A.; Hansen, M.; Ralfkiaer, E.; Spechit, L. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol. Oncol. 2006, 24, 146–150.
14. Stratagene Laboratory Tools software. Available online: http://www.stratagene.com/qpcr/links.asp (accessed on 1 June 2005).
15. Primer 3. Available online: http://primer3.sourceforge.net/(accessed on 16 October 2013).
16. Binderup, T.; Knigge, U.; Mellon, M.A.; Palnaes, H.C.; Kjaer, A. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology 2008, 87, 223–232.
17. Shebani, K.O.; Souba, W.W.; Finkelstein, D.M.; Stark, P.C.; Elgadi, K.M.; Tanabe, K.K.; Ott, M.J. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann. Surg. 1999, 229, 815–821.
18. Jemal, A.; Siegel, R.; Ward, E.; Murray,T.; Xu, J.; Thun, M.J. Cancer statistics, 2007. Ca—A Cancer J. Clin. 2007, 57, 43–66.
19. Panzuto, F.; Nasoni, S.; Falconi, M.; Corleto, M.M.; Capurso, G.; Cassetta, S.; di Fonzo, M.; Tornatore, V.; Milione, M.; Angeletti, S.; et al. Prognostic factors and survival in endocrine tumor patients: Comparison between gastrointestinal and pancreatic localization. Endocr. Relat. Cancer 2005, 12, 1083–1092.
20. Pape, U.F.; Berndt, U.; Müller-Nordhorn, J.; Bohmig, M.; Roll, S.; Koch, M.; Willich, S.N.; Wiedenmann, B. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr. Relat. Cancer 2008, 15, 1083–1097.
21. Oettle, H.; Post, S.; Neuhaus, P.; Gellert, K.; Langrehr, J.; Ridwelski, K.; Schramm, H.; Fahike, J.; Zuelke, C.; Burkart, C.; et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007, 297, 267–277.
22. Neoptolemos, J.P.; Stocken, D.D.; Friess, H.; Bassi, C.; Dunn, J.A; Hickey, H.; Beger, H.; Fernandez-Cruz, L.; Dervenis, C.; Lacaine, F.; et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004, 350, 1200–1210.
23. Fischer, B.; Lassen, U.; Mortensen, J.; Larsen, S.; Loft, A.; Bertelsen, A.; Ravn, J.; Clementsen, P.; Høgholm, A.; Larsen, K.; et al. Preoperative staging of lung cancer with combined PET-CT. N. Engl. J. Med. 2009, 361, 32–39.
24. Hutchings, M.; Loft, A.; Hansen, M.; Pedersen, L.M.; Berthelsen, A.K.; Keiding, S.; D’Amore, F.; Boesen, A.M.; Roemer, L.; Specht, L. Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 2006, 91, 482–489.
25. 18 F-FDG PET in patients with head and neck squamous cell cancer. AJR Am. J. Roentgenol. 2009, 192, W156-60.
26. Whiteford, M.H.; Whiteford, H.M.; Yee, L.F.; Ogunbiyi, O.A.; Dehdashti, F.; Siegel, B.A.; Birnbaum, E.H.; Fleshman, J.W.; Kodner, I.J.; Read, T.E. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis. Colon Rectum 2000, 43, 759–767.
27. 18 F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin. Cancer Res. 2010, 16, 978–985.
28. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J. Nucl. Med. 2004, 45, 22–29.
29. Tohma, T.; Okazumi, S.; Makino, H.; Cho, A.; Mochiduki, R.; Shuto, K.; Kudo, H.; Matsubara, K.; Gunji, H.; Ochiai, T. Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepatogastroenterology 2005, 52, 486–490.
30. 18 F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J. Nucl. Med. 2005, 46, 675–682.
31. 18 F-FDG uptake. J. Nucl. Med. 2005, 46, 1753–1759.
32. 18F-FDG. Cancer 2008, 112, 2447–2455.
33. Oberg, K.; Astrup, L.; Eriksson, B.; Falkmer, S.E.; Falkmer, U.G.; Gustafsen, J.; Haglund, C.; Knigge, U.; Vatn, M.H.; Välimäki, M. et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I—General overview. Acta Oncol. 2004, 43, 617–625.